Melanoma

Malaria drug Chloroquine helps fight treatment resistant brain cancer

After her brain cancer became resistant to chemotherapy and then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to live. Now a paper published in the journal eLife describes a new drug combination that has stabilized Rosendahl’s disease and increased both the quantity and quality of her life: Adding the …

Malaria drug Chloroquine helps fight treatment resistant brain cancer Read More »

Protein CPEB4 plays crucial role in melanoma

Spanish National Cancer Research Centre (CNIO) Melanoma Group researchers work tirelessly to identify biomarkers of tumor progression and to validate novel therapeutic targets in melanoma. In particular, their research focuses on discovering features that define the “fingerprint” of this tumor, features that distinguish it from other cancer types. The latest study in this area, published …

Protein CPEB4 plays crucial role in melanoma Read More »

Virtual clinical trials use mathematical modelling to predict melanoma response

Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling. A study led by Alexander “Sandy” Anderson, Ph.D., chair of IMO, and Eunjung Kim, Ph.D., an applied research scientist, shows how mathematical modeling can accurately predict patient responses …

Virtual clinical trials use mathematical modelling to predict melanoma response Read More »

Synthetic binding protein called "NS1 Monobody" found to inhibit common cancer causing (RAS) mutation

Monobody NS1 binds to H-RAS or K-RAS protein and blocksRAS function by disrupting the protein’s ability to form active molecular pairs. Credit: John P. O’Bryan, et al.  Researchers at the University of Illinois at Chicago have identified a new way to block the action of genetic mutations found in nearly 30 percent of all cancers. Mutations in …

Synthetic binding protein called "NS1 Monobody" found to inhibit common cancer causing (RAS) mutation Read More »